lutetium-lu-177-dotatate and Lymphopenia

lutetium-lu-177-dotatate has been researched along with Lymphopenia* in 1 studies

Trials

1 trial(s) available for lutetium-lu-177-dotatate and Lymphopenia

Article	Year
High clinical and morphologic response using European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:3 Bulky disease is an adverse prognostic factor for. We reviewed patients (pts) with at least one lesion of a transaxial diameter >4 cm who completed 1-2 cycles of. PRCRT with Topics: Adult; Aged; Chemoradiotherapy; Drug Administration Schedule; Female; Humans; Lymphopenia; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiopharmaceuticals; Thrombocytopenia	2017

Article

Year

High clinical and morphologic response using

European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:3

Bulky disease is an adverse prognostic factor for. We reviewed patients (pts) with at least one lesion of a transaxial diameter >4 cm who completed 1-2 cycles of. PRCRT with

Topics: Adult; Aged; Chemoradiotherapy; Drug Administration Schedule; Female; Humans; Lymphopenia; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiopharmaceuticals; Thrombocytopenia

2017